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Background: Preconditioning using lipopolysaccharide (LPS), a toll-like receptor 4 (TLR4) ligand, has
been demonstrated to reduce ischaemia/reperfusion injury (IRI) in some organs, but its effect in the liver
has not been elucidated. We examined the liver protective mechanism and correlated signalling pathway
of LPS preconditioning in mice.
Methods: BALB/c and TLR4 mutant mice underwent 90 min of 70% hepatic ischaemia. Lipopolysac-
charide (100 mg/kg) was injected intraperitoneally 20 h or 30 min before ischaemia. Liver damage after
reperfusion was examined using serum samples and liver specimens. To analyse the mechanism of
preconditioning in detail, phosphorylation of representative signalling mediators to nuclear factor-kB
(NF-kB) activation, Akt and interleukin-1 receptor-associated kinase-1 (IRAK-1), and expression of a
negative feedback inhibitor, suppressor of cytokine signalling-1 (SOCS-1), were evaluated by Western
blotting.
Results: Pretreatment with LPS only 20 h before ischaemia elicited a preconditioning effect; however,
preconditioning was absent in TLR4 mutant mice. Lipopolysaccharide significantly decreased serum
alanine aminotransferase, tumour necrosis factor-a, hepatocyte necrosis and NF-kB activity after reper-
fusion. Phosphorylated IRAK-1 was suppressed by LPS, whereas no difference was observed in phos-
phorylated Akt. Pre-ischaemic LPS provided early induction of SOCS-1.
Discussion: Late-phase LPS preconditioning provided liver protection against IRI through the down-
regulation of the TLR4 cascade derived from early induction of SOCS-1 during ischaemia/reperfusion.
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Introduction
Systemic circulation of lipopolysaccharide (LPS), a component of
the Gram-negative bacteria cell wall, can result in serious conse-
quences for patients, such as shock and disseminated intravascular
coagulation. These undesirable complications are caused by
stimulation of the toll-like receptor 4 (TLR4) signalling pathway,
which regulates the innate immune system against invasion by
pathogens and multiple other endogenous ligands.1 As a result of
TLR4 signalling, the transcription factor nuclear factor-kB (NF-
kB), which modulates induction of cytokines and expression of
proinflammatory genes, is activated.2 By contrast, LPS has also
been demonstrated to exert a tissue-protective effect in the heart,
brain, kidney and other organs.3 Pretreatment with a non-toxic
amount of LPS increases resistance to tissue damage after
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ischaemia/reperfusion (I/R), an effect designated as LPS
preconditioning.4–6
Preconditioning that attenuates ischaemia/reperfusion injury
(IRI) can be classified based on the protective timeframe and
mechanism.7–9 Early-phase preconditioning exhibits a large degree
of tissue protection for a short period compared with late-phase
preconditioning. Each class of preconditioning exerts specific pro-
tective mechanisms with corresponding signalling pathways, such
as through phosphatidylinositol 3 (PI3) kinase/Akt or TLR4.10–12
The PI3 kinase/Akt pathway has been demonstrated to be involved
in hepatic ischaemic preconditioning, an early-phase precondi-
tioning, by suppressing hepatocyte apoptosis.10 The PI3 kinase/
Akt pathway has also been associated with cardiac LPS
preconditioning, a late-phase event, which reduces myocardial
infarct size.3 By contrast, the TLR4 pathway has been reported to
participate in early-phase hepatic protection using high mobility
group box-1 (HMGB-1), a TLR4 ligand similar to LPS.12 It is
interesting that preconditioning with the same TLR4 ligand pro-
duces tissue protection in different phases and through the modu-
lation of different signalling pathways in the heart and liver.
Hepatic preconditioning with LPS has not been adequately
described in previous studies. Therefore, the present study aimed
to investigate the protective effect of LPS pretreatment against
liver IRI and the mechanism of LPS preconditioning.
Materials and methods
Animals and hepatic ischaemia
Male wild-type mice (BALB/c, C3H/HeN) and TLR4-mutant
mice (C3H/HeJ) (weight 20–30 g) were prepared for all
experiments.
All mice underwent laparotomy under general anaesthesia.
Warm hepatic ischaemia of 70% was induced using a microvas-
cular clip. Blood flow was recovered after 90 min of ischaemia. All
experimental procedures with animals were carried out according
to guidelines for the care and use of laboratory animals in place at
Kagawa University.
Experimental design
All BALB/c mice received intraperitoneal pretreatment with
100 mg/kg of either LPS or normal saline. The mice were divided
into an LPS-non-treated group (LPC[-]), which received normal
saline injection; an early-phase LPS preconditioning group (Early-
LPC), which underwent pretreatment with 100 mg/kg LPS 30 min
before ischaemia, and a late-phase LPS preconditioning group
(Late-LPC), which was subjected to 100 mg/kg LPS pretreatment
20 h before ischaemia, sustained ischaemia as previously
described and reperfusion. After pretreatment, mice were either
subjected to ischaemia for 90 min before reperfusion or killed at
the scheduled time-point. TLR4-mutant mice (C3H/HeJ) and the
corresponding wild-type mice (C3H/HeN) received pretreatment
with or without LPS before I/R induction.
Cytokine measurement
Serum concentrations of tumour necrosis factor-a (TNF-a) were
measured using enzyme-linked immunosorbent assay (ELISA)
kits (Pierce Biotechnology, Inc., Rockford, IL, USA).
Assessment of liver damage
Hepatic damage after I/R was evaluated by measurement of serum
alanine aminotransferase (ALT) levels and histological findings.
Histological assessment was based on the modified Suzuki’s
score,13 which grades necrotic areas on a scale of 0–4. A score of 0
indicates no evidence of necrosis, whereas a score of 4 represents
> 60% necrosis.
Sample preparation
All nuclear and cytoplasmic protein extracts were prepared from
homogenized liver specimens using a nuclear extraction kit
(Pierce Biotechnology, Inc.) according to the manufacturer’s
instructions. Protein concentrations of extracts were determined
using a BCA (bicinchoninic acid) protein assay kit (Pierce Bio-
technology, Inc.) and standardized.
SDS-PAGE and Western blotting
Cytoplasmic proteins were electrophoresed and transferred to
polyvinylidene difluoride membranes (Immobilon-P; Millipore
Corp., Bedford, MA, USA). After appropriate blocking, mem-
branes were incubated with primary antibodies: phosphorylated
Akt (1:1000; Cell Signalling Technology, Inc., Beverly, MA, USA);
phosphorylated interleukin-1 receptor-associated kinase-1
(IRAK-1) (1:1000; Cell Signalling Technology, Inc.), and suppres-
sor of cytokine signalling-1 (SOCS-1) (1:500; Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA). The membranes were then
incubated with horseradish peroxidase (HRP) conjugated second-
ary antibodies (Santa Cruz Biotechnology, Inc.) at the recom-
mended dilution. Target proteins were visualized using an
enhanced chemiluminescence system (Amersham Pharmacia,
Amersham, UK).
Electrophoretic mobility shift assay
Nuclear factor-kB DNA binding activity was evaluated by electro-
phoretic mobility shift assay (EMSA) using standardized nuclear
extracts as described above.
Quantitative reverse-transcription polymerase
chain reaction
Each specimen was snap-frozen in liquid nitrogen and stored at
-80 °C after sampling. Total RNA was isolated frommurine tissue
by guanidinium isothiocyanate-acid phenol extraction and quan-
tified by measuring absorbance at 260 nm. One mg of total RNA
was used for reverse transcription, and specific mRNAs were
determined by real-time polymerase chain reaction (PCR) using
Power SYBR Green PCR Master Mix (Applied Biosystems, Inc.,
Foster City, CA, USA) on ABI Prism 7000. Oligonucleotide
primers and probes were: TNF-a, forward primer: 5′-AGC CTG
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TAG CCC ACG TCG TA-3′ and TNF-a, reverse primer: 5′-TGG
CAC CAC TAG TTG GTT GTC T-3′, and SOCS-1, forward
primer: 5′-GCA TCC CTC TTAACC CGG TAC T-3′ and SOCS-1,
reverse primer: 5′-ATA AGG CGC CCC CAC TTA AT-3′. 18S
rRNA was amplified as an endogenous control. Primers and
probes for 18S rRNA were obtained from a Pre-Developed
TaqMan Assay Reagent Kit (Applied Biosystems AB, Stockholm,
Sweden).
Statistical analysis
Results are expressed as mean standard error of the mean
(SEM). Group comparisons were performed using Student’s t-test
or anova. Differences were considered significant at P < 0.05.
Results
Effect of LPS preconditioning on serum ALT
To examine the effect of LPS pretreatment against liver IRI,
100 mg/kg LPS was administered 20 h or 30 min before ischaemia.
Late-phase LPS pretreatment significantly reduced serum levels of
ALT compared with no pretreatment, whereas early-phase LPS
pretreatment did not (Fig. 1A). To analyse underlying factors,
expression of TNF-a, a pleiotropic cytokine which mediates mul-
tiple immune responses secondary to LPS stimulation, was mea-
sured by RT-PCR before induction of ischaemia. Expression of
TNF-a was 40-fold higher in the Early-LPC group than in the
Late-LPC group before ischaemia (Fig. 1B). This suggests that LPS
pretreatment 30 min before ischaemia leads to an inflammatory
state associated with the intense induction of cytokines in the
pre-ischaemic period.
Late-phase LPS pretreatment confers hepatic
protection
The Late-LPC group showed significantly less hepatic necrosis
than the LPC(-) group (Fig. 2A). However, early-phase LPS pre-
treatment resulted in the same level of liver injury after I/R as did
pretreatment without LPS. Liver specimens obtained from the
LPC(-) group and the Early-LPC group showed > 60% necrosis of
hepatocytes and severe sinusoidal congestion, whereas parenchy-
mal damage was minimal in the Late-LPC group (Fig. 2B).
Late LPS preconditioning attenuates NF-kB activity
independent of the PI3K/Akt pathway
We examined whether the protective effect of late-phase LPS pre-
conditioning was associated with the PI3K/Akt signalling pathway
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Figure 1 Lipopolysaccharide (LPS) pretreatment reduced serum levels of alanine aminotransferase (ALT) after ischaemia/reperfusion, but in
late-phase treatment only. (A) LPS (100 mg/kg) was administered 20 h or 30 min before ischaemia (n = 6). Mice underwent 90 min of
ischaemia and subsequent reperfusion. Serum levels of ALT in each sample were measured 6 h after reperfusion. (B) Expression of tumour
necrosis factor-a (TNF-a) was examined for evaluation of the pre-ischaemic inflammatory response by reverse-transcription polymerase
chain reaction (n = 6). As an endogenous control, the amplification of 18S rRNA was used. Results are expressed as mean  standard error
of the mean. *P < 0.05, compared with the LPC(-) group and the Early-LPC group. LPC(-), LPS-non-treated group; Late-LPC, late-phase
LPS preconditioning group; Early-LPC, early-phase LPS preconditioning group
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by Western blotting. No difference in Akt phosphorylation was
observed between the LPC(-) and Late-LPC groups (Fig. 3A). In
addition, binding activity of NF-kB was evaluated using EMSA to
confirm that liver protection was associated with NF-kB regula-
tion. Less NF-kB activity was observed in the LPS pretreated mice
compared with controls 1 h after reperfusion (Fig. 3B). Hence,
LPS preconditioning downregulated NF-kB, but did not involve
the PI3K/Akt signalling pathway.
Involvement of TLR4 in LPS preconditioning
The role of TLR4 signalling, which can also activate NF-kB, was
examined in LPS preconditioning using TLR4-mutant mice and
the associated wild type. Similar levels of hepatic injury occurred
in mutant mice after I/R both with and without LPS precondi-
tioning, including localized parenchymal necrosis and mild sinu-
soidal congestion (Fig. 4A). By contrast, LPS preconditioning
ameliorated the severe damage of IRI in wild-type mice (Fig. 4B).
These findings indicate that TLR4 signalling is involved in hepatic
protection after I/R.
Inhibition of inflammatory cascade via the
TLR4 pathway
Western blot analysis was performed to investigate whether LPS
preconditioning had an actual effect on the TLR4 pathway in
hepatic I/R. The phosphorylation of IRAK-1, a key molecule in
the TLR4 cascade that leads to NF-kB activation, was examined.
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Figure 2 Late-phase lipopolysaccharide (LPS) pretreatment attenuated liver parenchymal necrosis after ischaemia/reperfusion, whereas
early-phase pretreatment was unable to prevent liver damage. Mice were subjected to LPS pretreatment, ischaemia and reperfusion as
described above. Liver specimens were sampled 6 h after perfusion (n = 6). (A) Effect of LPS pretreatment on necrosis of hepatocytes
following ischaemia/reperfusion was evaluated according to the pathological damage score. (B) Liver sections of each group (haematoxylin
and eosin stain; original magnification ¥ 100). Results are expressed as mean  standard error of the mean. *P < 0.05, compared with the
LPC(-) group and the Early-LPC group. LPC(-), LPS-non-treated group; Late-LPC, late-phase LPS preconditioning group; Early-LPC,
early-phase LPS preconditioning group
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The Late-LPC group exhibited lower expression of phosphory-
lated IRAK-1 6 h after reperfusion in comparison with the LPC(-)
group (Fig. 5A). As an indicator of inflammatory progression,
serum levels of TNF-a were measured using ELISA (Fig. 5B).
Lipopolysaccharide preconditioning significantly reduced serum
TNF-a compared with negative controls. Overall, pre-ischaemic
LPS treatment appears to inhibit post-I/R inflammation via the
TLR4 cascade.
Modulation of the TLR4 pathway by induction
of SOCS-1
Post-ischaemic expression of SOCS-1, a feedback inhibitor of
TLR4 signalling, was examined to analyse its potential protective
effect against hepatic IRI. RT-PCR revealed a significant difference
in SOCS-1 expression 1 h after reperfusion between the LPC(-)
and Late-LPC groups (Fig. 6A). Lipopolysaccharide precondition-
ing led to earlier induction of SOCS-1 in the reperfusion period
(Fig. 6B). These data suggest that modulation of TLR4 signalling
through induction of SOCS-1 in the early phases of I/R contrib-
utes to the liver protection derived from LPS preconditioning.
Discussion
Since the initial report of hepatic injury after I/R by Toledo-
Pereyra and colleagues,14 many studies have been conducted to
clarify the mechanisms underlying this injury. The process of
hepatic injury during I/R has been elucidated in detail.15–17 Diverse
types of intrahepatic cells participate in the inflammatory
response triggered by circulatory blockade, including hepatocytes,
Kupffer cells, sinusoidal endothelial cells and neutrophils. More-
over, these cells produce reactive oxygen species and other proin-
flammatory mediators such as cytokines, chemokines and
adhesionmolecules. The interaction among these cells andmedia-
tors leads to the development of a complicated inflammatory
response induced by I/R. A series of inflammatory responses acti-
vates transcription factor NF-kB.18–20 NF-kB in turn regulates the
gene expression of many proinflammatory mediators, in particu-
lar TNF-a, which is induced in the relatively early ischaemic phase
and augments the subsequent inflammatory signal indirectly such
NF-κB
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Figure 3 Late-phase lipopolysaccharide (LPS) preconditioning
made no difference in the phosphorylation of Akt, but inhibited the
activation of transcription factor nuclear factor (NF)-kB. Mice under-
went 100 mg/kg LPS pretreatment 20 h before 90 min ischaemia and
reperfusion. Samples were obtained 1 h after reperfusion (n = 6). (A)
Effect of LPS preconditioning on the phosphorylation of Akt was
examined by Western blotting. (B) NF-kB binding activity was inves-
tigated by electrophoretic mobility shift assay using nuclear extracts
prepared from liver samples. LPC(-), LPS-non-treated group;
Late-LPC, late-phase LPS preconditioning group; Phospho-,
phosphorylated
C3H/HeN LPC(-) C3H/HeN Late-LPC
C3H/HeJ LPC(-) C3H/HeJ Late-LPC(A)
(B)
Figure 4 Toll-like receptor 4 (TLR4) signalling pathway was associ-
ated with hepatic protection provided by lipopolysaccharide (LPS)
preconditioning. TLR4-mutant mice (C3H/HeJ) and wild-type mice
for TLR4-mutant (C3H/HeN) were subjected to ischaemic proce-
dures for 90 min with or without LPS pretreatment. After 6 h of
reperfusion, both strains of mice were killed and liver specimens
were obtained. Liver sections of (A) mutant mice and (B) wild-type
mice (haematoxylin and eosin stain; original magnification ¥ 100).
LPC(-), LPS-non-treated group; Late-LPC, late-phase LPS precon-
ditioning group
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as by recruiting neutrophils.21 Therefore, NF-kB is considered to
represent a promising therapeutic target for suppressing IRI.
Several treatments have been investigated to reduce hepatic IRI
through direct or indirect inhibition of NF-kB activation.22,23 In
the liver, pretreatment that modulates PI3K/Akt signalling and
TLR4 signalling has been demonstrated to suppress I/R-induced
NF-kB activation.10–12 The PI3K/Akt pathway is crucial to cell
survival as it regulates apoptosis in response to various stimuli.24,25
Tissue protection through the inhibition of apoptosis in reper-
fused organs has been reported in hepatic ischaemic precondi-
tioning10 and cardiac LPS preconditioning.4 However, the TLR4
pathway protects the innate immune system from a variety of
endogenous or exogenous stimuli, including hepatic I/R.26–29
Accordingly, the negative regulation of this pathway may drive
preconditioning. Preconditioning by HMGB-1 in the liver has
been demonstrated to inhibit inflammatory signalling via the
TLR4 cascade.12 We found that control groups expressed similar
levels of phosphorylated Akt and higher levels of phosphorylated
IRAK-1 compared with LPS pretreatment groups. Hepatic LPS
preconditioning has been demonstrated to involve TLR4 signal-
ling, but not PI3K/Akt. As mentioned above, Ha et al. showed that
the PI3K/Akt pathway is associated with cardiac LPS precondi-
tioning.4 The current study has not elucidated the differences
between heart and liver in implicated signalling pathways of LPS
preconditioning.
Preconditioning, a tissue-protective procedure, has been devel-
oped in diverse organs because injury after I/R inflicts severe
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Figure 5 Lipopolysaccharide (LPS) preconditioning inhibited inflam-
matory response after ischaemia/reperfusion via the toll-like recep-
tor 4 (TLR4) signalling pathway. Mice underwent LPS pretreatment
and ischaemic procedures as described above. Serum and liver
samples were obtained 1 h and 6 h after reperfusion, respectively
(n = 6). (A) Western blotting showed the difference between the
LPC(-) group and the Late-LPC group in phosphorylation of
interleukin-1 receptor-associated kinase-1 (IRAK-1). (B) Serum levels
of tumour necrosis factor-a (TNF-a) were measured for evaluation of
the inflammation after reperfusion (n = 6). Results are expressed as
mean  standard error of the mean. *P < 0.05, compared with the
LPC(-) group. LPC(-), LPS-non-treated group; Late-LPC, late-phase
LPS preconditioning group; Phospho-, phosphorylated
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Figure 6 Lipopolysaccharide (LPS) preconditioning induced sup-
pressor of cytokine signalling-1 (SOCS-1) in the earlier post-
ischaemic period. Mice were subjected to pretreatment, ischaemia
and reperfusion as described above. Protein extracts were prepared
from liver parenchyma sampled after reperfusion (n = 5). Expression
of SOCS-1 was investigated using (A) reverse transcription poly-
merase chain reaction and (B) Western blotting. As an endogenous
control, the amplification of 18S rRNA was used. Results are
expressed as mean  standard error of the mean. *P < 0.05, com-
pared with the LPC(-) group. LPC(-), LPS-non-treated group; Late-
LPC, late-phase LPS preconditioning group
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damage under clinical conditions. Recently,many preconditioning
techniques, using non-lethal invasive procedures and drugs, have
been reported.9,30 Early-phase preconditioning provides protection
immediately after the procedure, which is maintained for 2–3 h.
Early preconditioning primarily acts through direct influence
upon parenchymal and non-parenchymal cellular function. By
contrast, late preconditioning produces protection after 12–24 h
and protects tissues for 3–4 days. Late-phase preconditioning
influences protein synthesis through the activation of several
stress-responsive genes. Although early preconditioning may exert
a larger protective effect, late preconditioningmay bemore appeal-
ing, given its longer effective duration.7,8 Some studies indicate that
LPS produces late preconditioning, whereas HMGB-1 produces
early preconditioning.4–6 In the present study, early LPS pretreat-
ment failed to provide hepatic protection. Histological assessment
exhibited the same level of hepatic necrosis in mice with and
without early LPS pretreatment. However, early LPS pretreatment
did produce extremely high TNF-a expression before ischaemia,
which suggests that a hyperinflammatory statemay accompany the
upregulation of signalling mediators. These differences in results
may be caused by inadequate recovery from the septic state in the
early pretreatment group. Lipopolysaccharide pretreatment
requires sufficient time to produce a preconditioning effect.
Low-dose LPS has been shown to induce tolerance to subse-
quent toxic doses of LPS and upregulate SOCS-1 and
interleukin-1 receptor-associated kinase M (IRAK-M), negative
feedback inhibitors of TLR4.31,32 We also demonstrated that LPS
preconditioning induced immediate upregulation of SOCS-1 in
the early reperfused period. In addition, HMGB-1 precondition-
ing has been reported to upregulate IRAK-M.12 Taken together,
pretreatment using a TLR4 ligand, such as LPS or HMGB-1,
appears to provide tissue protection against stressors by inducing
negative feedback inhibitors of this cascade.
In summary, we have demonstrated that pretreatment with LPS
attenuated liver injury following I/R. This liver-protective effect
was induced by pretreatment 20 h before ischaemia, but not
30 min before ischaemia. Lipopolysaccharide preconditioning
against liver IRI involves TLR4 signalling and its negative feedback
inhibitor, SOCS-1. Therefore, negative feedback inhibitors of the
TLR4 cascade may serve as therapeutic targets to reduce hepatic
IRI and other inflammatory diseases.
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